NewEdge Advisors’s Larimar Therapeutics LRMR Stock Holding History

NewEdge Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,121	Closed	-$11.9K	–	4186
2025 Q2	$11.9K	Buy	+4,121	New	+$9.54K	﹤0.01%	3141

Other funds holding LRMR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

NewEdge Advisors's LRMR Position: Q3 2025 in Review

NewEdge Advisors sold out of Larimar Therapeutics (LRMR) in Q3 2025, closing a stake of 4,121 shares — an estimated $11.9K sold.

NewEdge Advisors first reported a position in LRMR in Q2 2025 and held it in 1 quarter. The position peaked at $11.9K in Q2 2025. 136 funds tracked by Wall St. Rank hold LRMR as of Q3 2025.

NewEdge Advisors reported no remaining Larimar Therapeutics position as of Q3 2025 after selling out during the quarter.
NewEdge Advisors sold 4,121 Larimar Therapeutics shares in Q3 2025, an estimated $11.9K.
NewEdge Advisors first reported a position in Larimar Therapeutics in Q2 2025 and held it in 1 quarter.
NewEdge Advisors's Larimar Therapeutics position peaked at $11.9K in Q2 2025.
136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2025.

Based on NewEdge Advisors's 13F filing for Q3 2025, filed 17 Nov 2025.